Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus second-line chemotherapy for metastatic colorectal cancer
ChiCTR1800014478Phase 4Not yet recruiting
- Sponsor
- Yibin Second People's Hospital
- Start
- Feb 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Rivoceranib in colorectal cancer (CRC) (2 arms), sponsored by Yibin Second People's Hospital. Primary endpoint: Progression-free survival. Planned start Feb 2018; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR1800014478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014478.